Last $60.66 USD
Change Today +1.18 / 1.98%
Volume 457.8K
Q On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

quintiles transnational hold (Q) Snapshot

Open
$59.56
Previous Close
$59.48
Day High
$60.79
Day Low
$59.38
52 Week High
12/26/14 - $60.79
52 Week Low
01/27/14 - $45.25
Market Cap
7.8B
Average Volume 10 Days
980.4K
EPS TTM
$2.62
Shares Outstanding
127.9M
EX-Date
--
P/E TM
23.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for QUINTILES TRANSNATIONAL HOLD (Q)

quintiles transnational hold (Q) Related Businessweek News

No Related Businessweek News Found

quintiles transnational hold (Q) Details

Quintiles Transnational Holdings Inc., through its subsidiary, Quintiles Transnational Corp., provides biopharmaceutical development services and commercial outsourcing services in the Americas, Europe, Africa, and the Asia-Pacific. The company operates through two segments, Product Development and Integrated Healthcare Services. The Product Development segment provides project management and clinical monitoring services, including study design and operational planning, investigator/site recruitment, site and regulatory start up, patient recruitment, clinical monitoring, and project management for conducting various multi-site trials; and clinical trial support services comprising clinical data management, biostatistical, central laboratories, genomic laboratory, bioanalytical laboratories, cardiac safety and ECG, safety and pharmacovigilance, and phase I clinical pharmacology services. It also provides strategic planning and design services; and consulting services, such as product development strategy, regulatory and compliance, and process and IT implementation consulting services. The Integrated Healthcare Services segment offers commercial services comprising contract sales, market entry/market exit, integrated channel management, patient engagement, market access and commercialization consulting, and medical education services; communication and health engagement services, including digital patient, and brand and scientific communications services; and outcome-based services, such as observational studies, comparative effectiveness studies, and product and disease registry services. The company serves biopharmaceutical companies, including medical device and diagnostics companies. Quintiles Transnational Holdings Inc. was founded in 1982 and is based in Durham, North Carolina.

32,100 Employees
Last Reported Date: 10/30/14
Founded in 1982

quintiles transnational hold (Q) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.0M
Executive Chairman
Total Annual Compensation: $871.2K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.1M
Chief Customer & Governance Officer and Execu...
Total Annual Compensation: $838.4K
Consultant
Total Annual Compensation: $526.3K
Compensation as of Fiscal Year 2013.

quintiles transnational hold (Q) Key Developments

Quintiles Launches Marketed Product Maintenance Offering to Better Manage Established Products

Quintiles announced a new offering that combines its pharmacovigilance, regulatory dossier/label maintenance, benefit-risk management, and analytic expertise into one integrated solution. This solution will help biopharmaceutical companies better manage all activities required to maintain the licenses for their portfolio of marketed products. Underpinned by a fully-integrated technology platform, the new offering, called Marketed Product Maintenance (MPM), will provide biopharmaceutical companies with data-driven insights on the benefit-risk profiles of their products. These enhanced insights will enable customers to identify potential product risks, fulfill increasingly complicated regulatory requirements and help them make better decisions about their marketed products. By using technology and subject matter expertise to connect the post-approval requirements and license maintenance processes more effectively and efficiently, biopharmaceutical companies can generate greater return on investment from their portfolio of established products by redeploying resources on prioritized, growth-oriented products. These services will be delivered globally as an integrated and efficient turnkey solution, leveraging company's safety, regulatory, benefit-risk management research experience, as evidenced by: 99% on-time compliance for approximately 1.5 million clinical, post-marketing, and device safety reports processed globally since 2009; 100% of approximately 1,500 electronic common technical documents (eCTDs) submitted to the EU, U.S. and Canada passed technical validation.

Quintiles Transnational Holdings Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Full Year of 2014

Quintiles Transnational Holdings Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $1,400,034,000 compared to $1,195,839,000 a year ago. Income from operations was $149,142,000 compared to $125,259,000 a year ago. Income before income taxes and equity in earnings of unconsolidated affiliates was $132,470,000 compared to $94,398,000 a year ago. Net income was $92,733,000 compared to $66,584,000 a year ago. Net income attributable to the company was $92,654,000 compared to $66,769,000 a year ago. Diluted earnings per share were $0.71 compared to $0.50 a year ago. Adjusted EBITDA was $181,115,000 compared to $159,784,000 a year ago. Adjusted income from operations was $150,935,000 compared to $132,460,000 a year ago. Adjusted net income was $84,985,000 compared to $70,714,000 a year ago. Diluted adjusted earnings per share were $0.65 compared to $0.53 a year ago. Contributing to the adjusted net income growth were the increased service revenues, improved operating margins in both segments and $3.7 million less interest expense due to lower interest rates offset by the increase in the effective income tax rate compared to the For the nine months, the company reported total revenues of $4,048,910,000 compared to $3,720,360,000 a year ago. Income from operations was $431,458,000 compared to $335,321,000 a year ago. Income before income taxes and equity in earnings of unconsolidated affiliates was $369,321,000 compared to $223,074,000 a year ago. Net income was $268,057,000 compared to $153,093,000 a year ago. Net income attributable to the company was $267,957,000 compared to $153,595,000 a year ago. Diluted earnings per share were $2.03 compared to $1.22 a year ago. Net cash provided by operating activities was $175,797,000 compared to $177,911,000 a year ago. Acquisition of property, equipment and software was $57,782,000 compared to $73,940,000 a year ago. Adjusted EBITDA was $524,320,000 compared to $451,862,000 a year ago. Adjusted income from operations was $435,207,000 compared to $374,912,000 a year ago. Adjusted net income was $261,569,000 compared to $191,028,000 a year ago. Diluted adjusted earnings per share were $1.98 compared to $1.51 a year ago. Net debt outstanding, defined as total debt and capital lease obligations less cash and equivalents at September 30, 2014, was $1.4 billion compared to $1.27 billion at the end of December 2013. The decrease in operating cash flow reflects an increase in payments for taxes and less cash received from upfront payments under customer contacts, partially offset by lower cash paid for interest. The company provided earnings guidance for the full year of 2014. For the period, the company expects adjusted service revenue to be of $4.16 billion to $4.19 billion and increased diluted adjusted EPS to be of $2.61 to $2.68 per share, representing diluted adjusted EPS growth of 26.7% to 30.1% compared to 2013, with diluted GAAP earnings per share between $2.61 and $2.68 per share. The annual effective income tax rate is estimated to be approximately 30%.

Quintiles Transnational Holdings Inc. Presents at Credit Suisse Annual Healthcare Conference, Nov-11-2014 10:00 AM

Quintiles Transnational Holdings Inc. Presents at Credit Suisse Annual Healthcare Conference, Nov-11-2014 10:00 AM. Venue: The Biltmore, 2400 E Missouri Ave, Phoenix, AZ 85016, United States. Speakers: Thomas H. Pike, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
Q:US $60.66 USD +1.18

Q Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioanalytical Systems Inc $2.11 USD +0.02
Covance Inc $103.88 USD +0.15
ICON PLC $53.16 USD +0.50
INC Research Holdings Inc $25.91 USD -0.22
PAREXEL International Corp $57.51 USD +1.03
View Industry Companies
 

Industry Analysis

Q

Industry Average

Valuation Q Industry Range
Price/Earnings 23.5x
Price/Sales 1.9x
Price/Book NM Not Meaningful
Price/Cash Flow 22.7x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUINTILES TRANSNATIONAL HOLD, please visit www.quintiles.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.